FierceBiotechOriginal article
{"a":[{"_":"Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’","$":{"href":"/biotech/longeverons-phase-2b-stem-cell-flop-spurs-cost-cutting-exploration-all-options","hreflang":"en"}}]}
negativeNegative
AI Analysis
Summary
Longeveron's phase 2b study of a stem cell therapy for pediatric heart disease missed its primary endpoint. The failure prompts the cash-strapped biotech to explore strategic alternatives and implement cost-cutting measures.
Clinical Trial Data
Phase
2b
Primary Endpoint
Not Met
Outcome Details
missed primary endpoint
Importance:7/10
Sentiment:
-0.90
phase 2b failurestem cell therapypediatric heart diseasecost cuttingcash-strapped
Related Companies
Read the original article
Published by FierceBiotech on September 17, 2026 4:12 AM